Medicine and Dentistry
Breast Cancer
100%
Brain Metastasis
63%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
41%
PARP Inhibitor
35%
Disease
30%
Triple Negative Breast Cancer
29%
Olaparib
27%
Arm
26%
Prexasertib
23%
Programmed Death-Ligand 1
23%
Secondary Prevention
23%
Durvalumab
23%
Temozolomide
23%
Neoplasm
20%
Clinical Trial
19%
Biological Marker
18%
Metastatic Carcinoma
17%
Central Nervous System Metastasis
15%
Recurrent Ovarian Cancer
15%
Gamma Urogastrone
14%
Epidermal Growth Factor Receptor 2
14%
Blood Brain Barrier
14%
Malignant Neoplasm
13%
Metastatic Breast Cancer
13%
Radiation Therapy
13%
Endometrium Carcinoma
11%
Cell-Free DNA
11%
Checkpoint Kinase 1
11%
Targeted Therapy
11%
Endometrial Cancer
11%
Trastuzumab
11%
Cediranib
11%
Neurological Complication
11%
Cancer Therapy
11%
Treatment Response
11%
Dynamic Contrast-Enhanced MRI
11%
Neoadjuvant Chemotherapy
11%
Local Therapy
11%
Progression Free Survival
11%
Pharmacokinetics
9%
Central Nervous System
9%
Poly ADP Ribose Polymerase
8%
Hormone Receptor
8%
Ovarian Cancer
8%
Adverse Event
7%
Overall Survival
7%
Biopsy
6%
Whole Brain Radiotherapy
6%
Magnetic Resonance Imaging
6%
Immunocompetent Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
72%
Clinical Trial
55%
Breast Cancer
47%
Brain Metastasis
47%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
37%
Gamma Urogastrone
32%
Epidermal Growth Factor Receptor 2
32%
Disease
29%
Neoplasm
28%
Solid Malignant Neoplasm
27%
Glycan
23%
Cediranib
23%
Monoclonal Antibody
23%
Durvalumab
23%
Olaparib
23%
Temozolomide
23%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
23%
Triple Negative Breast Cancer
17%
Ovary Cancer
13%
Immunotherapy
13%
Metastatic Breast Cancer
13%
Metastasis
13%
Neutropenia
13%
Biological Marker
12%
Adverse Event
12%
Prexasertib
11%
Checkpoint Kinase 1
11%
Focal Adhesion Kinase
11%
Clinical Pharmacokinetics
11%
Cytotoxicity
11%
Antibody Drug Conjugate
11%
Fibrosis
11%
Programmed Death 1 Ligand 1
11%
Vasculotropin Receptor 1
11%
Docetaxel
11%
Endometrium Carcinoma
11%
Volume of Distribution
11%
Lapatinib
11%
Endometrium Cancer
11%
Integrin
11%
Phase I Trials
8%
Febrile Neutropenia
6%
Maximum Tolerated Dose
6%
Monotherapy
6%
Cytokine
5%
Pharmacokinetics
5%
Keyphrases
Phase I Study
47%
Brain Metastases
25%
Vascular Endothelial Growth Factor Receptor (VEGFR)
23%
Olaparib
23%
Cediranib
23%
BRCA Wild-type
23%
Prexasertib
23%
Female Cancer
23%
Durvalumab
23%
PARP Inhibitor (PARPi)
23%
Triple-negative Breast Cancer
20%
Breast Cancer
16%
Dose Escalation
15%
Human Epidermal Growth Factor Receptor 2 (HER2)
15%
Clinical Activity
13%
LY2606368
11%
Blood-brain Barrier
11%
Department of Defense
11%
HER2-positive Breast Cancer
11%
Programmed death-1 Inhibitor
11%
Cell-free DNA Analysis
11%
Operable Breast Cancer
11%
NEO-201
11%
Glycan Targeting
11%
Anticore
11%
Checkpoint Kinase 1 Inhibitor
11%
Biomarker Analysis
11%
Lapatinib
11%
Advanced Triple-negative Breast Cancer
11%
Neurologic Complications
11%
PD-L1 Inhibitor
11%
Neoadjuvant Therapy
11%
Young Women
11%
Young Breast Cancer
11%
Secondary Prevention
11%
Cancer Treatment
11%
European Organizations
11%
CNS Metastases
11%
Validation Trial
11%
ONC201
11%
Temozolomide
11%
Breast Cancer Brain Metastasis
11%
Docetaxel
11%
Locally Advanced
11%
T-DM1
11%
Passive Marker
11%
Safety Activity
11%
Biparatopic
11%
Multi-model System
11%
Multiple Assignment
11%
